Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q2 2026 Earnings Call Transcript

Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDT Company Participants Eugenia Litz - VP & Head of Investor Relations Robert Koremans - CEO & Director Michael McClellan - Chief Financial Officer Alberto Martinez - Executive Vice President of Specialty & Primary Care Business Unit Scott Pescatore - Executive Vice President of Rare Diseases Business Unit Conference Call Participants Charles Pitman - Barclays Bank PLC, Research Division Kirsty Ross-Stewart - BNP Paribas, Research Division Presentation Operator Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the Recordati First Half 2026 Results Conference Call. [Operator Instructions] At this time, I would like to turn the conference over to Ms. Eugenia Litz, Vice President of Investor Relations of Recordati. Please go ahead, madam.

Eugenia Litz VP & Head of Investor Relations Thank you, and good afternoon, everyone. I'm pleased to be here today with Rob Koremans, our CEO; and Mike McClellan, our CFO, who will present results for the first half of 2026. Also joining for the Q&A session will be Scott Pescatore, Executive Vice President of Rare Diseases; Alberto Martinez, Executive Vice President of Specialty and Primary Care; and Milan Zdravkovic, Executive Vice President of R&D. As always, the presentation is available in the Investors section of our website. It is now my pleasure to pass the call over to Rob. Please go ahead.

Robert Koremans CEO & Director Thank you, Eugenia, and good afternoon, everyone. Thank you for joining us today. We are very pleased with our performance in the first half of the year. We delivered another period of strong financial results, continued to execute well across businesses and maintained the momentum that positions us to achieve our full year objectives. Revenue increased to EUR 1.4 billion, representing a